Prot# IFN3958g: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single-and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults with Mildly Active Systemic Lupus Erythematosus

Project: Research project

Project Details

StatusFinished
Effective start/end date8/16/07 → 8/16/10

Funding

  • Genentech, Inc (IFN3958g)